GLORIA

GEOMAR Library Ocean Research Information Access

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    In: Cells, MDPI AG, Vol. 10, No. 12 ( 2021-12-14), p. 3533-
    Kurzfassung: Acetylcholinesterase (AChE) inhibition is a key element in enhancing cholinergic transmission and subsequently relieving major symptoms of several neurological and neuromuscular disorders. Here, the inhibitory potential of geraniol and its mechanism of inhibition against AChE were elucidated in vitro and validated via an in silico study. Our in vitro enzyme inhibition kinetics results show that at increasing concentrations of geraniol and substrate, Vmax did not change significantly, but Km increased, which indicates that geraniol is a competitive inhibitor against AChE with an IC50 value 98.06 ± 3.92 µM. All the parameters of the ADME study revealed that geraniol is an acceptable drug candidate. A docking study showed that the binding energy of geraniol (−5.6 kcal mol−1) was lower than that of acetylcholine (−4.1 kcal mol−1) with AChE, which exhibited around a 12.58-fold higher binding affinity of geraniol. Furthermore, molecular dynamics simulation revealed that the RMSD of AChE alone or in complex with geraniol fluctuated within acceptable limits throughout the simulation. The mean RMSF value of the complex ensures that the overall conformation of the protein remains conserved. The average values of Rg, MolSA, SASA, and PSA of the complex were 3.16 Å, 204.78, 9.13, and 51.58 Å2, respectively. We found that the total SSE of AChE in the complex was 38.84% (α-helix: 26.57% and β-sheets: 12.27%) and remained consistent throughout the simulation. These findings suggest that geraniol remained inside the binding cavity of AChE in a stable conformation. Further in vivo investigation is required to fully characterize the pharmacokinetic properties, optimization of dose administration, and efficacy of this plant-based natural compound.
    Materialart: Online-Ressource
    ISSN: 2073-4409
    Sprache: Englisch
    Verlag: MDPI AG
    Publikationsdatum: 2021
    ZDB Id: 2661518-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    In: Biomedicine & Pharmacotherapy, Elsevier BV, Vol. 143 ( 2021-11), p. 112156-
    Materialart: Online-Ressource
    ISSN: 0753-3322
    RVK:
    Sprache: Englisch
    Verlag: Elsevier BV
    Publikationsdatum: 2021
    ZDB Id: 1501510-5
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    In: Journal of Cellular Biochemistry, Wiley, Vol. 122, No. 9 ( 2021-09), p. 1216-1228
    Kurzfassung: Leishmaniasis is a neglected tropical disease caused by trypanosomatid parasite belonging to the genera Leishmania . Leishmaniasis is transmitted from one human to other through the bite of sandflies. It is endemic in around 98 countries including tropical and subtropical regions of Asia, Africa, Southern America, and the Mediterranean region. Sterol C‐24 methyltransferase ( Ld SMT) of Leishmania donovani (L. donovani ) mediates the transfer of CH3‐group from S‐adenosyl methionine to C‐24 position of sterol side chain which makes the ergosterol different from cholesterol. Absence of ortholog in human made it potential druggable target. Here, we performed virtual screening of library of natural compounds against Ld SMT to identify the potential inhibitor for it and to fight leishmaniasis. Gigantol, flavan‐3‐ol, and parthenolide showed the best binding affinity towards Ld SMT. Further, based on absorption, distribution, metabolism, and excretion properties and biological activity prediction, gigantol showed the best lead‐likeness and drug‐likeness properties. Therefore, we further elucidated its antileishmanial properties. We found that gigantol inhibited the growth and proliferation of promastigotes as well as intra‐macrophagic amastigotes. Gigantol exerted its antileishmanial action through the induction of reactive oxygen species in dose‐dependent manner. Our study, suggested the possible use of gigantol as antileishmanial drug after further validations to overcome leishmaniasis.
    Materialart: Online-Ressource
    ISSN: 0730-2312 , 1097-4644
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2021
    ZDB Id: 1479976-5
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    In: Journal of Cellular Biochemistry, Wiley, Vol. 122, No. 9 ( 2021-09), p. 1037-1047
    Kurzfassung: Leishmaniasis is a neglected tropical disease caused by the protozoan parasite Leishmania . It is endemic in more than 89 different countries worldwide. Sterol alpha‐14 demethylase ( Ld SDM), a sterol biosynthetic pathway enzyme in Leishmania donovani , plays an essential role in parasite survival and proliferation. Here, we used a drug repurposing approach to virtually screen the library of the Food and Drug Administration (FDA)‐approved drugs against Ld SDM to identify the potential lead‐drug against leishmaniasis. Zafirlukast and avodart showed the best binding with Ld SDM. Zafirlukast was tested for in vitro antileishmanial assay, but no significant effect on L. donovani promastigotes was observed even at higher concentrations. On the other hand, avodart profoundly inhibited parasite growth at relatively lower concentrations. Further, avodart showed a significant decrease in the number of intra‐macrophagic amastigotes. Avodart‐induced reactive oxygen species (ROS) in the parasites in a dose‐dependent manner. ROS induced by avodart led to the induction of apoptosis‐like cell death in the parasites as observed through annexin V/PI staining. Here, for the first time, we reported the antileishmanial activity and its possible mechanism of action of FDA‐approved drug, avodart, establishing a nice example of the drug‐repurposing approach. Our study suggested the possible use of avodart as an effective antileishmanial agent after further detailed validations.
    Materialart: Online-Ressource
    ISSN: 0730-2312 , 1097-4644
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2021
    ZDB Id: 1479976-5
    SSG: 12
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 5
    Online-Ressource
    Online-Ressource
    Sciencedomain International ; 2021
    In:  Journal of Pharmaceutical Research International ( 2021-08-17), p. 175-186
    In: Journal of Pharmaceutical Research International, Sciencedomain International, ( 2021-08-17), p. 175-186
    Kurzfassung: Aims: Tobacco smoking is a major health issue in Saudi Arabia, particularly among the student population. Smoking is one of the major risk factors in the genesis of coronary atherosclerosis and the development of coronary heart disease. This study aimed to evaluate the effect of cigarette and shisha smoking on atherogenic indexes, lipid profile and hematological parameters of undergraduate smokers at Majmaah University. Methodology: This cross-sectional study was conducted between November 2019 and March 2020, at the Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Al-Majmaah, enrolling 100 undergraduate students (35 cigarette smokers, 30 shisha smokers, 35 non-smokers). The subjects were asked to fast overnight and early morning blood samples were collected and analyzed to measure lipid parameters, complete blood cell count and LDH. Lipid parameters were used to calculate lipid indexes and atherogenic indexes. Results: Compared with non-smokers, cigarette and shisha smokers had significantly higher levels of TC, TG, LDL-C and VLDL-C, but significantly lower levels of HDL-C. The values of comprehensive lipid indexes, including non-HDL-C, TC/HDL-C, TG/HDL-C, LDL-C/HDL-C, atherogenic index (AI), lipoprotein combine index (LCI), and atherogenic index of plasma (AIP) were all significantly higher in cigarette and shisha smokers. Hematological parameters were found to be within normal reference range, however when compared with non-smokers, cigarette and shisha smokers has significantly higher values of complete blood cell count, except for lymphocytes and mean corpuscular hemoglobin concentration (MCHC) which were significantly lower. LDH was also found to be elevated in cigarette and shisha smokers. Conclusion: The findings of this study shows that, both cigarette and shisha smokers have abnormal lipid profile suggesting dyslipidemia. Prediction of early atherosclerosis through the atherogenic indexes was observed to be significantly higher in shisha smokers than in cigarette smokers. Therefore, shisha smoking has more adverse effects on the health status of adult smokers. This study adds to the accumulating evidence on the harmful effects of shisha smoking, which is a growing epidemic among young smokers, and calls for the awareness of the possible consequences of developing early atherogenesis.
    Materialart: Online-Ressource
    ISSN: 2456-9119
    Sprache: Unbekannt
    Verlag: Sciencedomain International
    Publikationsdatum: 2021
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 6
    In: Entropy, MDPI AG, Vol. 24, No. 5 ( 2022-04-23), p. 593-
    Kurzfassung: Neurodegenerative disorders involve various pathophysiological pathways, and finding a solution for these issues is still an uphill task for the scientific community. In the present study, a combination of molecular docking and dynamics approaches was applied to target different pathways leading to neurodegenerative disorders such as Alzheimer’s disease. Initially, abrineurin natural inducers were screened using physicochemical properties and toxicity assessment. Out of five screened compounds, a pentacyclic triterpenoid, i.e., Soyasapogenol B appeared to be the most promising after molecular docking and simulation analysis. Soyasapogenol B showed low TPSA (60.69), high absorption (82.6%), no Lipinski rule violation, and no toxicity. Docking interaction analysis revealed that Soyasapogenol B bound effectively to all of the targeted proteins (AChE, BuChE MAO-A, MAO-B, GSK3β, and NMDA), in contrast to other screened abrineurin natural inducers and inhibitors. Importantly, Soyasapogenol B bound to active site residues of the targeted proteins in a similar pattern to the native ligand inhibitor. Further, 100 ns molecular dynamics simulations analysis showed that Soyasapogenol B formed stable complexes against all of the targeted proteins. RMSD analysis showed that the Soyasapogenol B–protein complex exhibited average RMSD values of 1.94 Å, 2.11 Å, 5.07 Å, 2.56 Å, 3.83 Å and 4.07 Å. Furthermore, the RMSF analysis and secondary structure analysis also indicated the stability of the Soyasapogenol B–protein complexes.
    Materialart: Online-Ressource
    ISSN: 1099-4300
    Sprache: Englisch
    Verlag: MDPI AG
    Publikationsdatum: 2022
    ZDB Id: 2014734-X
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 7
    In: ACS Omega, American Chemical Society (ACS), Vol. 6, No. 3 ( 2021-01-26), p. 2318-2327
    Materialart: Online-Ressource
    ISSN: 2470-1343 , 2470-1343
    Sprache: Englisch
    Verlag: American Chemical Society (ACS)
    Publikationsdatum: 2021
    ZDB Id: 2861993-6
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 8
    Online-Ressource
    Online-Ressource
    Bentham Science Publishers Ltd. ; 2019
    In:  Protein & Peptide Letters Vol. 26, No. 5 ( 2019-05-29), p. 371-376
    In: Protein & Peptide Letters, Bentham Science Publishers Ltd., Vol. 26, No. 5 ( 2019-05-29), p. 371-376
    Kurzfassung: Leishmaniasis is caused by a protozoan parasite, Leishmania. It is common in more than 98 countries throughout the world. Due to insufficient availability of antileishmanial chemotherapeutics, it is an urgent need to search for new molecules which have better efficacy, low toxicity and are available at low cost. Objectives: There is a high rate of diabetic cases throughout the world that is why we planned to test the antileishmanial activity of glyburide, an effective sugar lowering drug used for the treatment of diabetes. In this study, glyburide showed a significant decrease in the parasite growth and survival in vitro in a dose-dependent manner. Methods: Anti-leishmanial activity of glyburide was checked by culturing Leishmania donovani promastigotes in the presence of glyburide in a dose and time dependent manner. Docking study against Leishmania donovani-Trypanothione synthetase (LdTrySyn) protein was performed using Autodock Vina tool. Results: Growth reversibility assay shows that growth of treated parasite was not reversed when transferred to fresh culture media after 7 days. Moreover, docking studies show efficient interactions of glyburide with key residues in the catalytic site of Leishmania donovani- Trypanothione synthetase (LdTrySyn), a very important leishmanial enzyme involved in parasite’s survival by detoxification of Nitric Oxide (NO) species, generated by the mammalian host as a defense molecule. Thus this study proves that the drug-repurposing is a beneficial strategy for identification of new and potent antileishmanial molecules. Conclusion: The results suggest that glyburide binds to LdTrySyn and inhibits its activity which further leads to the altered parasite morphology and inhibition of parasite growth. Glyburide may also be used in combination with other anti-leishmanial drugs to potentiate the response of the chemotherapy. Overall this study provides information about combination therapy as well as a single drug treatment for the infected patients suffering from diabetes. This study also provides raw information for further in vivo disease model studies to confirm the hypothesis.
    Materialart: Online-Ressource
    ISSN: 0929-8665
    Sprache: Englisch
    Verlag: Bentham Science Publishers Ltd.
    Publikationsdatum: 2019
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 9
    In: Pharmaceuticals, MDPI AG, Vol. 14, No. 9 ( 2021-09-18), p. 937-
    Kurzfassung: Alzheimer’s disease (AD) is a progressive neurological disorder that affects 50 million people. Despite this, only two classes of medication have been approved by the FDA. Therefore, we have planned to develop therapeutics by multitarget approach. We have explored the library of 2029 natural product-like compounds for their multi-targeting potential against AD by inhibiting AChE, BChE (cholinergic pathway) MAO-A, and MOA-B (oxidative stress pathway) through in silico high-throughput screening and molecular dynamics simulation. Based on the binding energy of these target enzymes, approximately 189 compounds exhibited a score of less than −10 kcal/mol against all targets. However, none of the control inhibitors exhibited a binding affinity of less than −10 kcal/mol. Among these, the top 10 hits of compounds against all four targets were selected for ADME-T analysis. As a result, only F0850-4777 exhibited an acceptable range of physicochemical properties, drug-likeness, pharmacokinetics, and suitability for BBB permeation with high GI-A and non-toxic effects. The molecular dynamics study confirmed that F0850-4777 remained inside the binding cavity of targets in a stable conformation throughout the simulation and Prime-MM/GBSA study revealed that van der Waals’ energy (ΔGvdW) and non-polar solvation or lipophilic energy (ΔGSol_Lipo) contribute favorably towards the formation of a stable protein–ligand complex. Thus, F0850-4777 could be a potential candidate against multiple targets of two pathophysiological pathways of AD and opens the doors for further confirmation through in vitro and in vivo systems.
    Materialart: Online-Ressource
    ISSN: 1424-8247
    Sprache: Englisch
    Verlag: MDPI AG
    Publikationsdatum: 2021
    ZDB Id: 2193542-7
    SSG: 15,3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 10
    In: Drug Development Research, Wiley, Vol. 82, No. 8 ( 2021-12), p. 1154-1161
    Kurzfassung: Leishmaniasis is a vector‐borne disease caused by around 20 species of Leishmania . The main clinical forms of leishmaniasis are cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). VL is caused by Leishmania infantum in Central and South America, Mediterranean Basin, Middle East, and by L. donovani in Asia and Africa. Sterol C‐24 methyltransferase ( Ld SMT) of L. donovani is a transferase enzyme of the sterol biosynthesis pathway. This pathway is one of the major targets for drug developments in Leishmania. Due to insufficient evidence about the exact function of SMT inside the cell and the uniqueness of the SMT enzyme in the Leishmania parasites made it a significant target for an effective drug development approach. We performed virtual screening of the Food and Drug Administration (FDA)‐approved drug library against Ld SMT and found simeprevir, an antiviral drug on top in the binding score. It showed a significant binding affinity with Ld SMT. The binding was supported by hydrogen bonds and several other interactions. Simeprevir inhibited L. donovani growth of promastigotes with 50% inhibitory concentration (IC 50 ) of 51.49 ± 5.87 μM. Further studies showed that simeprevir induced ROS generation in 44.7% of parasites at 125‐μM concentration. Here, we for the first time reported simeprevir as an antileishmanial lead molecule using a drug repurposing approach.
    Materialart: Online-Ressource
    ISSN: 0272-4391 , 1098-2299
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2021
    ZDB Id: 1500191-X
    SSG: 15,3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...